Empowering Hope: Pfizer Shares Encouraging Results from Phase 2 Trial of Ponsegromab for Cancer Cachexia Patients
Empowering Cancer Patients with Pfizer’s Breakthrough Study A Beacon of Hope In a groundbreaking development, Pfizer Inc. has announced a significant milestone in the battle against cancer cachexia. The Phase 2 study of ponsegromab, a monoclonal antibody targeting growth differentiation factor-15 (GDF-15), has shown promising results in improving body weight in individuals with cancer cachexia…